Edwards Lifesciences (EW)
(Delayed Data from NYSE)
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$68.54 USD
+4.00 (6.20%)
Updated Oct 8, 2024 04:00 PM ET
After-Market: $68.53 -0.01 (-0.01%) 7:58 PM ET
3-Hold of 5 3
C Value F Growth F Momentum F VGM
Zacks News
TFX vs. EW: Which Stock Is the Better Value Option?
by Zacks Equity Research
TFX vs. EW: Which Stock Is the Better Value Option?
Is it the Right Time to Hold EW Stock in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' Critical Care divestiture bodes well for its Structural Heart portfolio. Yet, macroeconomic issues raise worry for its operations.
TFX vs. EW: Which Stock Should Value Investors Buy Now?
by Zacks Equity Research
TFX vs. EW: Which Stock Is the Better Value Option?
Why Is Globus Medical (GMED) Down 0.2% Since Last Earnings Report?
by Zacks Equity Research
Globus Medical (GMED) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
BD Stock Falls After Acquisition of Edwards' Critical Care Group
by Zacks Equity Research
BDX expands its smart care portfolio by acquiring Edwards Lifesciences' Critical Care group, now BD Advanced Patient Monitoring, strengthening AI-driven health solutions.
EW Stock Dips Following the Divestiture of Critical Care Wing
by Zacks Equity Research
Edwards completes the sale of its Critical Care operations and announces a $1 billion share repurchase program.
EW Stock to Benefit From Favorable RHEIA Trial Data on TAVI
by Zacks Equity Research
Edwards' first all-female TAVI Trial demonstrates favorable outcomes for women receiving Edwards valves.
Why Is Waters (WAT) Down 2.2% Since Last Earnings Report?
by Zacks Equity Research
Waters (WAT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Penumbra (PEN) Up 20% Since Last Earnings Report?
by Zacks Equity Research
Penumbra (PEN) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why Is Hologic (HOLX) Down 3.4% Since Last Earnings Report?
by Zacks Equity Research
Hologic (HOLX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Edwards Lifesciences (EW) Up 19.4% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Edwards Lifesciences (EW) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
TFX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TFX vs. EW: Which Stock Is the Better Value Option?
Should You Hold Edward Lifesciences (EW) in Your Portfolio Now?
by Zacks Equity Research
Edward Lifesciences' (EW) promising TAVR business and the Critical Care divestment move bode well in the long term.
TFX or EW: Which Is the Better Value Stock Right Now?
by Zacks Equity Research
TFX vs. EW: Which Stock Is the Better Value Option?
Edwards Lifesciences (EW) Reliance on International Sales: What Investors Need to Know
by Zacks Equity Research
Evaluate Edwards Lifesciences' (EW) reliance on international revenue to better understand the company's financial stability, growth prospects and potential stock price performance.
Edwards Lifesciences (EW) Q2 Earnings Meet Mark, Margins Crash
by Zacks Equity Research
Edwards Lifesciences (EW) reports strong contributions from the TMTT product group in the second quarter of 2024.
Edwards Lifesciences (EW) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
by Zacks Equity Research
While the top- and bottom-line numbers for Edwards Lifesciences (EW) give a sense of how the business performed in the quarter ended June 2024, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Edwards Lifesciences (EW) Q2 Earnings Match Estimates
by Zacks Equity Research
Edwards Lifesciences (EW) delivered earnings and revenue surprises of 0% and 16.19%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?
The Zacks Analyst Blog Highlights Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences
by Zacks Equity Research
Boston Scientific, Thermo Fisher Scientific, Align Technology and Edwards Lifesciences are part of the Zacks Top Analyst Blog.
Can These 4 MedTech Stocks Hit Targets This Earnings Season?
by Urmimala Biswas
Here is a sneak peek into how four MedTech bigshots, BSX, TMO, ALGN and EW, are expected to fare in their second-quarter results, slated to be released tomorrow.
Earnings Preview: Integra LifeSciences (IART) Q2 Earnings Expected to Decline
by Zacks Equity Research
Integra (IART) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Edwards Lifesciences (EW) Buys Innovalve to Boost TMVR Solutions
by Zacks Equity Research
Edwards Lifesciences (EW) exercises the option to acquire Innovalve Bio-Medical Ltd., strengthening its TMVR technology portfolio and addressing unmet needs in structural heart disease.
Edwards Lifesciences (EW) Reports Next Week: Wall Street Expects Earnings Growth
by Zacks Equity Research
Edwards Lifesciences (EW) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is a Beat Likely for Edwards Lifesciences (EW) in Q2 Earnings?
by Zacks Equity Research
Edwards Lifesciences' (EW) TMTT segment's PASCAL platform is likely to have maintained strong growth momentum in the second quarter globally, backed by its portfolio of differentiated therapies.
Can Elevance Health (ELV) Beat Q2 Earnings on Lower Expenses?
by Zacks Equity Research
Elevance Health's (ELV) second-quarter results are likely to be aided by improved product revenues, commercial fee-based membership growth, and lower expenses.